The clinical efficacy and real-world effectiveness of approved disease-modifying therapies, including nusinersen, onasemnogene abeparvovec, and risdiplam are summarized, underscoring significant improvements in survival, motor milestones, and quality of life, particularly with early treatment initiation.
Andrej Belančić, Elvira Meni Maria Gkrinia, Yun-Wah Lam et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.